ATE336231T1 - Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung - Google Patents

Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Info

Publication number
ATE336231T1
ATE336231T1 AT02801623T AT02801623T ATE336231T1 AT E336231 T1 ATE336231 T1 AT E336231T1 AT 02801623 T AT02801623 T AT 02801623T AT 02801623 T AT02801623 T AT 02801623T AT E336231 T1 ATE336231 T1 AT E336231T1
Authority
AT
Austria
Prior art keywords
solvent
mixing zone
precipitation
producing crystalline
recirculating
Prior art date
Application number
AT02801623T
Other languages
English (en)
Inventor
James E Hitt
Christopher J Tucker
Jonathan C Evans
Cathy A Curtis
Sonke Svenson
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE336231T1 publication Critical patent/ATE336231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02801623T 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung ATE336231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31556001P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE336231T1 true ATE336231T1 (de) 2006-09-15

Family

ID=23224987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801623T ATE336231T1 (de) 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Country Status (6)

Country Link
US (1) US20030049323A1 (de)
EP (1) EP1423096B1 (de)
AT (1) ATE336231T1 (de)
CA (1) CA2458889C (de)
DE (1) DE60214012T2 (de)
WO (1) WO2003032951A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
JP5207432B2 (ja) * 2003-04-29 2013-06-12 エム・エス・ディー・オス・ベー・フェー アンチ溶媒凝固プロセス
JP4891773B2 (ja) 2003-05-22 2012-03-07 アプライド ナノシステムズ ベー．フェー． 微小粒子の生成
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
EP1727520A2 (de) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
WO2006028074A1 (ja) * 2004-09-07 2006-03-16 Mitsubishi Chemical Corporation 微粒子化された物質の製造方法および微粒子化された物質
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2012753A2 (de) * 2006-04-28 2009-01-14 Schering Corporation Verfahren zur ausscheidung und isolierung von 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexan-amid-verbindungen durch kontrollierte ausscheidung und pharmazeutische formulierungen damit
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2178518A2 (de) * 2007-07-13 2010-04-28 Bend Research, Inc Nanopartikel mit ionisierbaren und schwach wasserlöslichen zellulose-polymeren
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2010003811A1 (en) * 2008-07-11 2010-01-14 Basf Se Amphiphilic proteins as morphology modifiers
KR101907411B1 (ko) 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
EP2618816A4 (de) * 2010-09-22 2014-10-29 Map Pharmaceuticals Ltd Aerosol-zusammensetzung zur verabreichung von medikamenten
US20120311822A1 (en) * 2011-06-10 2012-12-13 Culkin Joseph B Solute crystallizing apparatus
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
EP2601973A1 (de) 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
WO2018136909A1 (en) * 2017-01-23 2018-07-26 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
CN109011674B (zh) * 2018-09-11 2020-08-11 安徽东至广信农化有限公司 一种用于硝基氯苯制备的蒸酸器
US20220378704A1 (en) 2019-10-10 2022-12-01 Bayer Aktiengesellschaft Process for the preparation of a nanoparticulate active ingredient
WO2026013055A1 (en) * 2024-07-09 2026-01-15 Hovione Farmaciência S.A., Methods and systems for preparing feed solutions for spray drying

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US624617A (en) * 1899-05-09 Insecticide
SU1126202A3 (ru) * 1976-05-28 1984-11-23 Институт Фор Атомэнерги (Фирма) Способ непрерывной многостадийной кристаллизации из раствора
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6315966B1 (en) * 1996-07-05 2001-11-13 Haarmann & Reimer Gmbh Crystallization process and device
DE19738085C1 (de) * 1997-09-01 1998-12-03 Basf Ag Verfahren zur Herstellung von Feststoffen durch Fällung
US5908589A (en) * 1997-12-08 1999-06-01 Twenty-First Century Research Corporation Methods for separating catalyst from oxidation mixtures containing dibasic acids
EP0930073B1 (de) * 1998-01-14 2004-08-04 National Research Development Corporation of India Verfahren zur Herstellung eines spermiziden Mittels
US6607651B2 (en) * 1998-09-10 2003-08-19 Cws Parts Company Process and system for treating the discharge stream from an ion exchanger
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
TW526172B (en) * 1999-06-30 2003-04-01 Sumitomo Chemical Co A process for producing pentacyl-type crystalline zeolites and a process for producing ε-caprolactam using the same
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions

Also Published As

Publication number Publication date
WO2003032951A1 (en) 2003-04-24
CA2458889C (en) 2011-06-21
DE60214012T2 (de) 2006-12-21
US20030049323A1 (en) 2003-03-13
EP1423096A1 (de) 2004-06-02
EP1423096B1 (de) 2006-08-16
DE60214012D1 (de) 2006-09-28
CA2458889A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
DE60214012D1 (de) Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
DE50005599D1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikro- und nanopartikeln mittels eines mikromischers
SE9501384D0 (sv) Process for the preparation of respirable particles
ES2194579B1 (es) Metodo de produccion de fibra que tiene polvo mineral funcional y fibra producida a partir del mismo.
DE60029457D1 (de) Verfahren zur herstellung von feinkörnigen medizinischen substanzen
ATE179886T1 (de) Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung
ATE199828T1 (de) Verfahren zur konditionierung von substanzen
YU66003A (sh) Postupak za izdvajanje hemiceluloza iz biomase koja sadrži hemiceluloze kao i biomasa i hemiceluloze koje se mogu dobiti primenom ovog postupka
ATE251228T1 (de) Verfahren zur herstellung von pulvermischungen bzw. verbundpulver
ATE382671T1 (de) Verfahren zur herstellung von agglomeratteilchen
BR0008872B1 (pt) processo para a produção de formas de dosagem sólidas, e, forma de dosagem sólida.
DE60027695D1 (de) Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
EP1688169A4 (de) Verfahren zur herstellung von feinen teilchen einer organischen verbindung
DE50205571D1 (de) Verfahren zur Herstellung von direkt tablettierbaren Beta-Mannit
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
DE60119711D1 (de) Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
PT1583538E (pt) Utilização da 3-metoxi-pregnenolona para a preparação de um medicamento destinado a tratar as doenças neurodegenerativas
ATE305000T1 (de) Sysntheseverfahren zur herstellung von indolylquinonen und mono- und bis-indolylquinone, die durch das verfahren hergestellt sind
JP2003520794A5 (de)
ATE323429T1 (de) Biologisches verfahren zur herstellung eines hämeisenpräparats und daraus hergestellte nahrungsmittelprodukte
GB0120123D0 (en) Preparation of microparticles
ATE298567T1 (de) Pharmazeutische zusammensetzung enthaltend ibuprofen und ein verfahren zur deren herstellung
ATE342298T1 (de) Verfahren zur herstellung von kleinen sphärischen partikeln, die mindestens ein wasserunlösliches lineares polysaccharid enthalten
DE50301507D1 (de) 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties